This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biancone, L. Articles by Camussi, G. Search for Related Content PubMed PubMed Citation Articles by Biancone, L. Articles by Camussi, G.

Platelet-activating Factor Inactivation by Local Expression of Platelet-activating Factor Acetyl-Hydrolase Modifies Tumor Vascularization and Growth¹

Department of Internal Medicine, University of Torino, 10126 Torino, Italy [L. B., V. C., L. D. S., S. R., G. C.], and ICOS Corporation, Bothell, Washington 98021 [L. W. T.]

Purpose: Platelet-activating factor (PAF), a phospholipid mediator of inflammation, has been recently detected on tumor cells but its effect in tumor development is largely undefined.

Experimental Design: To address its potential role in tumor biology, we inhibited intratumor PAF activity by engineering tumor cell lines to express plasma PAF-acetylhydrolase (PAF-AH), the major PAF-inactivating enzyme, and studied their behavior in vitro and in vivo.

Results: When transfected with PAF-AH, KS-Imm human Kaposi’s sarcoma cells implanted in SCID mice and B16F10 mouse melanoma cells implanted in syngenic C57Bl/6J mice showed significantly reduced vascularization and growth allowing longer survival compared with control tumors. The amounts of bioactive PAF extracted from PAF-AH-transfected tumors were significantly reduced. In vitro, expression of PAF-AH did not influence cell proliferation, whereas it inhibited PAF-dependent cell motility in Kaposi’s sarcoma cells that express PAF-receptor but not in melanoma cells that did not express it. On the other hand, PAF-induced endothelial tubulogenesis in Matrigel was inhibited by incubation with supernatant from PAF-AH-transfected melanoma cells, indicating that PAF-AH inhibits in vitro neoangiogenesis.

Conclusions: We demonstrated that in situ PAF inactivation affects tumor vascularization and growth through inhibition of neoangiogenesis and, in the case of cells expressing PAF receptor, also tumor cell motility.

This article has been cited by other articles:

				M. Aponte, W. Jiang, M. Lakkis, M.-J. Li, D. Edwards, L. Albitar, A. Vitonis, S. C. Mok, D. W. Cramer, and B. Ye Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR/Src/FAK/Paxillin in Ovarian Cancer Cancer Res., July 15, 2008; 68(14): 5839 - 5848. [Abstract] [Full Text] [PDF]

				S. Doublier, M. Ceretto, E. Lupia, S. Bravo, B. Bussolati, and G. Camussi The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase Clin. Cancer Res., October 1, 2007; 13(19): 5710 - 5718. [Abstract] [Full Text] [PDF]

				K. Heon Seo, H.-M. Ko, H.-A Kim, J.-H. Choi, S. Jun Park, K.-J. Kim, H.-K. Lee, and S.-Y. Im Platelet-Activating Factor Induces Up-regulation of Antiapoptotic Factors in a Melanoma Cell Line through Nuclear Factor-{kappa}B Activation. Cancer Res., May 1, 2006; 66(9): 4681 - 4686. [Abstract] [Full Text] [PDF]

				V. O. Melnikova, A. A. Mourad-Zeidan, D. C. Lev, and M. Bar-Eli Platelet-activating Factor Mediates MMP-2 Expression and Activation via Phosphorylation of cAMP-response Element-binding Protein and Contributes to Melanoma Metastasis J. Biol. Chem., February 3, 2006; 281(5): 2911 - 2922. [Abstract] [Full Text] [PDF]

				J. S. Owen, R. L. Wykle, M. P. Samuel, and M. J. Thomas An improved assay for platelet-activating factor using HPLC-tandem mass spectrometry J. Lipid Res., February 1, 2005; 46(2): 373 - 382. [Abstract] [Full Text] [PDF]